SEONGNAM, South Korea–(BUSINESS WIRE)–GI CELL, Inc. announced today that it has entered into a research license and option Agreement with Optieum Biotechnologies, Inc. (Japan). Under the agreement, Optieum Biotechnologies will provide GI CELL with scFv antibodies directed against hematological tumor targets generated through Optieum Biotechnologies’ Eumbody System. GI CELL will carry out feasibility studies and […]